A Phase 2 Multi-Center Investigation of Efficacy of ABI-009 (nab-rapamycin) in Patients with Advanced Malignant Perivascular Epithelioid Tumors (PEComa)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AADi LLC
Start Date
December 1, 2015
End Date
November 30, 2021
Administered By
Duke Cancer Institute
Awarded By
AADi LLC
Start Date
December 1, 2015
End Date
November 30, 2021